Aim: Individuals with amnestic mild cognitive impairment (aMCI) are at a high risk to develop Alzheimer's disease (AD). We compared CSF levels of biomarkers of amyloidosis (Ab 1-42 ) and neurodegeneration (p-Tau 181 ) in individuals with aMCI and with subjective cognitive impairment (SCI) in order to ascertain diagnostic accuracy and predict the odds ratio associated with aMCI. Methods: We collected CSF of individuals clinically diagnosed with aMCI (33) and SCI (12) 
Introduction
Mild cognitive impairment (MCI) is a disorder situated in the continuum between normal cognition and dementia. According to National Institute on Aging and the Alzheimer's Association (NIA-AA), the clinical characterization of MCI requires the presence all items below: (1) self-or informant -reported cognitive complain, (2) objective cognitive impairment, (3) preserved independence in functional abilities, and (4) no dementia. Individuals with MCI ascertained according to these core clinical criteria could be further sub classified into two categories: amnestic MCI (aMCI) if performance on neuropsychological tests of episodic memory is poor, and non-amnestic MCI (naMCI) in the case of poor performance on tests covering cognitive domains other than memory (Petersen et al., 2014) .
Only a proportion of individuals with MCI progress to AD (Alzheimer's disease). According to criteria established by NIA-AA, the use of biomarkers may aid in identifying etiological MCI subtypes by differentiating between MCI due to AD (i.e.: prodromal AD) and MCI that is unlikely to be due to AD (Albert et al., 2011; Dubois et al., 2014) .
Many biomarkers have been studied to support the clinical diagnosis of AD. Nonetheless, few have successfully defined AD signature. The most consistent ones have been related to compounds of neuritic plaques such as the b-amyloid protein (Ab ) and the main constituent of the neurofibrillary tangles, i.e., the hyperphosphorylated Tau protein (p-Tau 181 ) . They are reported to be altered at least 5-10 years before dementia diagnosis (Jack et al., 2013) . However, diagnostic accuracies of CSF biomarkers in MCI are still to be defined.
Although aMCI is a well-defined entity, it may be more difficult for non-specialists to proper diagnose this condition in their practice. In this sense, an exam that helps to discriminate normal aging from aMCI would be welcomed (Brandt, 2001) . Moreover, accurate identification of prodromal AD would become crucial when a disease-modifying drug becomes a reality (Cavedo et al., 2014) .
Based on core criteria above we measured and compared the concentration of (Ab 1-42 and p-Tau 181 ), in individuals clinically diagnosed with aMCI and with subjective cognitive impairment https://doi.org/10.1016/j.brainres.2017.10.008 0006-8993/Ó 2017 Elsevier B.V. All rights reserved.
(SCI) in a manner to ascertain the diagnostic accuracy and verify the odds ratio to have aMCI. Table 1 compares the demographics characteristics and neuropsychological scores between aMCI and SCI groups. Mean age was 67.9 ± 5.4 years and the majority was women (71.1%). There was a significant difference in median verbal memory test subscore of the Consortium to Establish a Registry for Alzheimer's Disease (VM-CERAD) (Bertolucci et al., 1998) between aMCI and SCI groups (p: .041). No differences were found when we analyzed scores of Geriatric Depression Scale (GDS) (Almeida and Almeida, 1999) (p: .724) and Clock-Drawing Test (CDT) (Shulman et al., 1993) (p: .825 ) between aMCI and SCI. Our sample was composed mostly of a Caucasian population, as which reflects the demographics of the Southern Brazilian population. Only one individual in each group was African-Brazilian. 
Results

Discussion
As expected, the concentration of Ab 1-42 protein was significantly diminished in aMCI subjects than among SCI. However, pTau 181 protein was not different between groups. These results are in accord with the recently proposed biomarker behavior hypothetical model of AD (Jack et al., 2010) . According to this model, CSF Ab 1-42 levels declines before the p-Tau 181 increases. It is possibly that CSF p-Tau 181 levels only start to increases expressively as neurodegeneration advances. Considering this model, we can infer that at the moment the markers were measured at our sample, CSF p-Tau 181 concentration in aMCI may not have raised expressively yet. In fact, p-Tau 181 only increase in the CSF later than Ab 1-42 starts to decrease (Buchhave et al., 2012) .
Although we found no significant difference in levels of pTau 181 , we verified a linear association of this protein with Ab 1-42, suggesting that they could be influenced by common mechanisms and/or influence each other. p-Tau 181 /Ab 1-42 ratio displayed significant difference between groups at our study. This coefficient is frequently utilized because it presumes a link between bamyloid and p-Tau pathways (Shaw et al., 2009 ). Indeed, pTau 181 /Ab 1-42 ratio was already reported (1) to predict cognitive decline in cognitively normal elderly (Fagan et al., 2007) , (2) to differentiate patients with AD from individuals without objective cognitive impairment (Ferreira et al., 2014) , and (3) to predict MCI progression to AD (Ferreira et al., 2014) .
Patients with AD dementia tends to have lower levels of CSF Ab 1-42 and higher levels of CSF p-Tau 181 than individuals without cognitive impairment (Blennow et al., 2010) . It has been reported Ab 1-42 levels are reduced in about 50% among individuals with AD relatively to age-matched people without cognitive impairment (Holtzman, 2011) . Although there are no established cutoff values for these CSF biomarkers general acceptable, some studies suggests cutoffs for CSF Ab 1-42 positivity in AD, which below 650 pg/mL when utilizing immunoenzymatic assays (Blennow et al., 2015) . p-Tau 181 thresholds usually vary above 60 and 80 pg/mL at the demential phase of the disease (Tang et al., 2014b) .
Cutoff points for Ab 1-42 and p-Tau 181 are still scarce and even unclear for aMCI individuals. A recent meta-analysis described that the levels of Ab 1-42 in aMCI individuals ranged from 172.6 ± 53.5 to 622.9 ± 275.6 pg/mL, whereas among healthy cognitively people they vary between 383.5 ± 101.8 and 1020 ± 230 pg/mL. However, none of these studies have direct compared aMCI to SCI. This metaanalysis suggests that there is no established threshold which can distinguish AD or aMCI from healthy cognitively individuals (Mo et al., 2015) . Although this study does not differentiate aMCI from SCI, some older studies compared CSF Ab 1-42 levels in general MCI individuals and healthy cognitively people (Herukka et al., 2005; Maruyama et al., 2001) . One reported that CSF Ab 1-42 levels did not differ significantly between cognitively normal subjects and MCI groups (Maruyama et al., 2001) , and other showed that values of CSF Ab 1-42 were significantly lower in progressive MCI group than in progressive and stable MCI groups (Herukka et al., 2005) .
The broad variation at the measurements of these biomarkers between studies and laboratories is only one of the difficulties in determining homogenous cutoff points (Tang et al., 2014a) . It might results from differences in CSF sample handling techniques, analytical procedures and kits. Cases selection criteria and resultant difference in sample characteristics are other problems. Standardization and quality control of these procedures may reduce the disparity and increase the utility of these CSF biomarkers (Samtani et al., 2013) . To find the best cutoff values we used the Youden index. This is a standardized and objective method to determine diagnostic cutoff points. Youden index evaluates the maximum potential effectiveness of a biomarker by choosing the best values in terms of test accuracy, taking in consideration both sensibility and specificity (Ruopp et al., 2008; Youden, 1950) . Such cutoff points, however, are dependent of several variables, such as study population and phase of disease. In this sense, it would be important that other cross-sectional studies on aMCI be conducted in different regions of the globe in order to find their best own distinctive cutoff point to differentiate aMCI from SCI. At our study, individuals with Ab 1-42 < 823 pg/mL were 6.0 times more likely to be diagnosed with aMCI, with reasonable accuracy. At the ratio p-Tau 181 /Ab 1-42, individuals with >0.071 were at 4.6 increased odds to have aMCI. Thus, among the CSF biomarkers studied here, CSF Ab 1-42 concentration was the best analyte for detection of aMCI subjects (ROC AUC: 0.768). Thereby, indicating that CSF Ab 1-42 might be the most single informative biomarker for prodromal AD. To our knowledge, no previous study has measured CSF biomarkers that discriminates exclusively aMCI individuals from SCI and identified cut off values and odds ratio to have aMCI, independently from previous neuropsychological and clinical evaluation. Our finding is important in order to correctly identify people who are at an imminent risk to progress to Alzheimer's disease dementia. We also aim to help non-specialists to properly diagnose aMCI and differentiate it from normal aging in clinical practice.
As expected, performance on VM-CERAD was significantly lower at aMCI group than at SCI. This finding probably means that aMCI cases and SCI individuals were well allocated. Conversely, GDS and CDT were not different between aMCI and SCI. Depression may be a cause of cognitive deficits or simulate aMCI. Our result probably means that depressed individuals were adequately excluded from our sample. In turn, CDT evaluates more executive function and visuospatial organization than memory itself. Vascular mild cognitive impairment is characterized by more impairment in executive functions and gait apraxia than is AD (Román and Royall, 1999) . Therefore, it was also expected that there will be no differences in CDT scores between our pure aMCI individuals and SCI. In fact, this finding also suggests that we have appropriately excluded MCI cases other than the purely amnestic ones.
Limitations of our study include the relatively small sample size and the fact that it is a case-control study, therefore general causality cannot be inferred. Strengths include simultaneous analysis of CSF biomarkers and neuropsychological evaluation in a group at high risk for developing AD. Moreover, biomarkers measures and cognitive and affective tests were conducted by blind persons, using validated methods. 
Conclusion
To our knowledge, this is the first study that evaluated CSF Ab 1-42 to discriminate exclusively aMCI individuals from SCI and identified cut off values and odds ratio of to have aMCI. Moreover, we found no value for CSF p-Tau 181 vis-à-vis CSF Ab 1-42 alone in predicting aMCI diagnosis.
Methods and materials
Study participants and clinical classification
We included thirty-three subjects with aMCI, and twelve individuals with SCI, without evidence of objective impairment, in the study. All were sixty years or older. They were referred to a memory clinic of Southern Brazil called ''Hospital de Clínicas de Porto Alegre". The sample size was based in a conservative estimation of AD's pathology among aMCI (70%) and SCI (10%). Considering a power of 90%, significance of 5% and 1/3 of losses (Markesbery, 2010) .
Participants were submitted to an evaluation that was performed blindly by a behavioral neurologist and a neuropsychologist, and included a structured clinical interview, a full neurological examination, and neuropsychological assessment. NIA-AA criteria for aMCI was used (Albert et al., 2011; Petersen et al., 2014) and corroborated by Clinical Dementia Rating (CDR) (Morris, 1993) . Cases fulfilled the criteria for aMCI and scored 0.5 on CDR, and SCI were individuals who had no evidence of objective cognitive decline by NIA-AA criteria and scored CDR: 0.
We excluded subjects who had evidence of dementia, stroke, cerebrovascular disease, Parkinson's disease, depression or other neurological disease that potentially cause cognitive impairment.
A questionnaire was applied in order to assess the following socio demographic data: age, sex, occupation and years of schooling.
Neuropsychological assessments
We utilized the VM-CERAD, Brazilian validated adaptation (Bertolucci et al., 1998) . In order to assess verbal episodic memory function this evaluation was performed by a certified and blind neuropsychologist. The final score was composed by a possible sum of 30 points for the word list learning, 10 points for word list recall and 10 points for word list recognition (total of 50 possible points) (Chandler et al., 2005) . The 0-5 points version of CDT was also utilized (Shulman et al., 1993) . The GDS 15-item version, translated and validated to Brazilian portuguese was applied (Almeida and Almeida, 1999) . Presence of significant depressive symptomatology was considered for all subjects who scored !6 points in the scale.
CSF analysis
All participants underwent a fasted lumbar puncture to obtain CSF samples. Briefly, CSF (5 ml) was collected in polypropylene tubes and immediately centrifuged (4000g Â 10 min) at 4°C and then stored at À80°C until assay. We used commercially available ELISA kits to determine levels of Ab 1-42 (Innotest b-amyloid1-42, Fujirebio-Europe, Gent, Belgium) and p-Tau 181 (Innotest Phospho-Tau181P, Fujirebio-Europe) following the manufacturers' recommendations. CSF tests were performed blindly after clinical evaluation, in duplicate, and the laboratory technician was also blinded to any clinical and demographic information about the study participants.
Statistical analysis
Statistical analyses were performed using SPSS (the Statistical Package for Social Sciences) version 20. To compare gender distribution between the groups, a Chi-square test was performed. Subsequently, Mann-Whitney U tests were performed to compare clinical, neuropsychological and biomarker data between the groups. A linear regression analysis was used to verify the relationship between proteins. Receiver operating characteristic (ROC) curve analyses were used to obtain area under the curve (AUC), that express the probability of a positive case test randomly chosen will exceed the outcome of a randomly chosen negative case. The optimal cutoff values were determined by calculating the maximal sum of sensitivity and specificity (i.e., maximizing the Youden index (Youden, 1950) . The accuracy of the tests was determined by the proportion of true results (both true positives and true negatives) among the total number of cases examined. Logistic linear regression was performed to verify the odds ratio. All results were showed as CI95% and p value <.05 was considered significant. Values were adjusted for age.
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